7365-45-9

Basic information

• Product Name: HEPES
• Synonyms: 4-(2-hydroxyethyl)-1-piperazineethanesulfonicaci;hepesfreeacid;4-(2-HYDROXYETHYL)-1-PIPERAZINEETHANESULFONIC ACID;4-(2-HYDROXYETHYL)PIPERAZINE-1-ETHANESULFONIC ACID;2-[4-(2-HYDROXYETHYL)-1-PIPERAZINE]ETHANESULFONIC ACID;2-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]ETHANESULFONIC ACID;LABOTEST-BB LT00138109;LABOTEST-BB LT00233156
• CAS NO: 7365-45-9
• Molecular Formula: C₈H₁₈N₂O₄S
• Molecular Weight: 238.3
• EINECS: 230-907-9
• Product Categories: Biochemistry;Good's Buffers;Buffer;ReagentsBiological Buffers;AlphabeticalMolecular Biology;Biological Buffers;BioUltra Buffers;BioUltraMolecular Biology;DNA&RNA Purification;Molecular Biology Reagents;Zwitterionic
• Mol File: 7365-45-9.mol

Chemical Properties

• Melting Point: 234-238 °C
• Boiling Point: 408℃[at 101 325 Pa]
• Appearance: White/powder
• Density: 1.07 g/mL at 20 °C
• Vapor Pressure: 0Pa at 25℃
• Refractive Index: n20/D 1.339
• Storage Temp.: 2-8°C
• Solubility: H2O: 1 M at 20 °C, clear, colorless
• PKA: 7.5(at 25℃)
• Water Solubility: Soluble
• Stability: Stable. Combustible. Incompatible with strong oxidizing agents. Protect from moisture.
• Merck: 14,4654
• BRN: 883043
• CAS DataBase Reference: HEPES(CAS DataBase Reference)
• NIST Chemistry Reference: HEPES(7365-45-9)
• EPA Substance Registry System: HEPES(7365-45-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25-22-36-26
• WGK Germany: 1
• RTECS: TL6809000
• TSCA: Yes
• Hazardous Substances Data: 7365-45-9(Hazardous Substances Data)

Usage

Uses

Used in Biological Research:
HEPES is used as a hydrogen ion buffer for maintaining a constant pH range in various biological experiments. It is particularly useful in cell culture applications, where it helps maintain physiological pH levels. The concentration used is typically between 10-50mmol/L, with 20mmol/L being a common concentration for achieving buffer ability in nutrient solutions.
Used in Cell Culture:
HEPES is used as a buffering component in the preparation of cell culture media. It is commonly found in solutions such as Hank's balanced salt solution, Dulbecco's modified eagle's medium, and no-glucose DMEM, which are used for the preparation of tissue slices.
Used in Tissue Culture:
HEPES buffered saline is a tissue culture buffer that helps maintain the pH of cell culture. It is particularly useful in in vitro experiments on Mg, where it helps control the pH of the surrounding environment.
Used in Conductance Measurements:
HEPES is used as a component of buffers in localized conductance measurements on the basolateral side of culture inserts to examine cation selectivity.

Biological Activity

HEPES is a multi purpose HEPES buffer used in cell culture and other biological research. Working pH range in aqueous solution: 6.8 - 8.2. Does not form complexes with metal ions. Used in cell culture media.

Biological Activity

Multi purpose buffer used in biological research.

Purification Methods

Crystallise the acid from hot EtOH and water. It is a useful buffer. [Beilstein 23 V 376.]

InChI:InChI=1/C8H18N2O4S/c11-7-5-9-1-3-10(4-2-9)6-8-15(12,13)14/h11H,1-8H2,(H,12,13,14)/p+1

Synthetic route

1-(2-hydroxyethyl)piperazine (103-76-4) + sodium 2-hydroxyethanesulfonate (1562-00-1) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
Stage #1: 1-(2-hydroxyethyl)piperazine; sodium 2-hydroxyethanesulfonate In methanol at 50℃; for 5.5h; Stage #2: With 5percent by weight of raffinate In water Solvent; Temperature;	85.6%

1-(2-hydroxyethyl)piperazine (103-76-4) + Na-salt of 2-chloroethane-1-sulfonic acid (15484-44-3) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
In water at 85 - 105℃; for 0.5h; pH=10; Temperature;	84.7%

1-(2-hydroxyethyl)piperazine (103-76-4) + ammonium vinylsulfonate (86761-62-8) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
Stage #1: 1-(2-hydroxyethyl)piperazine; ammonium vinylsulfonate In water at 60℃; for 4h; Stage #2: With sulfuric acid at 0℃; for 1h;

1-(2-hydroxyethyl)piperazine (103-76-4) + sodium vinylsulfonate (3039-83-6) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
Stage #1: 1-(2-hydroxyethyl)piperazine; sodium vinylsulfonate In water at 60 - 120℃; for 3h; Stage #2: With oxalic acid at 20℃; for 1h; Temperature; Reagent/catalyst;

1-(2-hydroxyethyl)piperazine (103-76-4) + potassium vinyl sulfonate (7308-65-8) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
Stage #1: 1-(2-hydroxyethyl)piperazine; potassium vinyl sulfonate In water at 50℃; for 3.5h; Stage #2: With sulfuric acid at 40℃; for 1h;

1-(2-hydroxyethyl)piperazine (103-76-4) + ethenesulfonic acid (1184-84-5) → N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9)

Conditions	Yield
Stage #1: 1-(2-hydroxyethyl)piperazine; ethenesulfonic acid With sodium hydroxide In water at 40℃; for 3.5h; Stage #2: With oxalic acid at 20℃; for 1h; Temperature; Reagent/catalyst;

1,1′-(1,4-butanediyl)bis(2-methylbenzimidazole) (1059536-93-4) + silver carbonate + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → [Ag2(N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonate))(1,1'-(1,4-butanediyl)bis(2-methylbenzimidazole))]*2H2O

Conditions	Yield
In ethanol mixt. of Ag salt, acid and imidazole ligand was stirred at room temp. for 30 min; ammonia added dropwise; slowly evapd. at room temp.; elem. anal.;	68%

2,3,4,5-tetrahydro-2-oxo-1,5-ethanolbenzazepine (102586-88-9) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → (N,N-dimethylamino)ethyl 1,2,3,4-tetrahydroquinoline-4-propanoate (104876-18-8)

Conditions	Yield
In water at 25℃; Rate constant;

N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → Glyoxal (131543-46-9) + 2-[2-(2-Hydroxy-ethylamino)-ethylamino]-ethanesulfonic acid

Conditions	Yield
With (batho)2CuII (batho = 2,9-dimethyl-4,7-diphenyl-1,10-phenanthrolinedisulfonate); water at 25℃; for 24h; Rate constant; Mechanism; pH 8; other substituted ethylenediamine;

deoxyguanosine 5'-monophosphate 2-methylimidazolide + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → 2'-deoxyguanosine 5'-monophosphate (902-04-5) + 2-[4-(2-{[(2R,3S,5R)-5-(2-Amino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphoryloxy}-ethyl)-piperazin-1-yl]-ethanesulfonic acid + C20H24N10O13P2(2-) + C30H35N15O19P3(3-)

Conditions	Yield
With sodium chloride; magnesium chloride; polycytidylate In water at 23℃; for 480h; pH=7.85; Kinetics; Product distribution; Further Variations:; Reagents; Condensation; dimerization; oligomerization; hydrolysis;

C15H18ClMnN3O3 (1313369-50-4) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → C8H17N2O4S(1-)*C15H16N3O2(1-)*Mn(2+)

Conditions	Yield
With sodium carbonate; sodium chloride In water at 25℃; pH=7.4;

zinc diacetate (557-34-6) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → zinc(II) oxide

Conditions	Yield
With sodium hydroxide In water at 110℃; for 0.283333h; pH=7.4; pH-value; Concentration; Reagent/catalyst; Sonication; Microwave irradiation;

zinc(II) chloride (7646-85-7) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → zinc hydroxide chloride hydrate

Conditions	Yield
With sodium hydroxide In water at 110℃; for 0.283333h; pH=7.4; Sonication; Microwave irradiation;

N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) + 1-ethyl-3-methylimidazolium hydroxide → C6H11N2(1+)*C8H17N2O4S(1-) (1612259-40-1)

Conditions	Yield
In water at 20℃; for 12h;

tetramethyl ammoniumhydroxide (75-59-2) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → C4H12N(1+)*C8H17N2O4S(1-) (79661-24-8)

Conditions	Yield
In water at 20℃; for 12h;

tetraethylammonium hydroxide (77-98-5) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → C8H20N(1+)*C8H17N2O4S(1-) (79661-25-9)

Conditions	Yield
In water at 20℃; for 12h;

tetra(n-butyl)ammonium hydroxide (2052-49-5) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → 2-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-ethanesulfonatetetrabutyl-ammonium; (113599-06-7)

Conditions	Yield
In water at 20℃; for 12h;

cholin hydroxide (123-41-1) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → cholinium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate

Conditions	Yield
In aq. buffer for 12h;

dATP (1927-31-7) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → C18H30N7O9PS

Conditions	Yield
With apelin-12; thermococcus kodakaraensis primase protein; magnesium acetate; serum albumin In glycerol at 70℃; for 0.5h; Enzymatic reaction;

C10H13N2O8(3-)*2Na(1+)*H(1+) + C25H22N4O5Zn + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → 6,6'-((1E,1'E)-((2E,2'E)-((2-hydroxy-5-methyl-1,3-phenylene)bis(methanylylidene))bis(hydrazine-2,1-diylidene))bis(methanylylidene))bis(3-methoxyphenol)

Conditions	Yield
In water; dimethyl sulfoxide pH=7.2;

C10H13N2O8(3-)*2Na(1+)*H(1+) + C25H23CdN4O5(1+) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → 6,6'-((1E,1'E)-((2E,2'E)-((2-hydroxy-5-methyl-1,3-phenylene)bis(methanylylidene))bis(hydrazine-2,1-diylidene))bis(methanylylidene))bis(3-methoxyphenol)

Conditions	Yield
In water; dimethyl sulfoxide pH=7.2;

C13H16N8O6P(1-) + 5'-adenosine monophosphate (61-19-8) + N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (7365-45-9) → C18H29N7O10PS(1-) + C23H28N13O12P2(1-) + P1,P2-diadenosine-5’-diphosphate

Conditions	Yield
Stage #1: 5'-adenosine monophosphate With hydrogenchloride; sodium hydroxide In water pH=5.5; Stage #2: C13H16N8O6P(1-); N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid With methyl isocyanate; acetaldehyde; magnesium chloride for 16h; pH=8; Inert atmosphere;

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 1562-00-1 sodium 2-hydroxyethanesulfonate 
• 86761-62-8 ammonium vinylsulfonate 
• 3039-83-6 sodium vinylsulfonate 
• 7308-65-8 potassium vinyl sulfonate 
• 1184-84-5 ethenesulfonic acid 
• 15484-44-3 Na-salt of 2-chloroethane-1-sulfonic acid 

Downstream Products

• 902-04-5 2'-deoxyguanosine 5'-monophosphate 

Relevant articles and documents

Preparation method of piperazine ethanesulfonic acid derivative (by machine translation)

The reaction is carried out in such a manner that the reaction proceeds relatively, more thoroughly by reducing the side, reaction of the reaction system, in a manner such that the reaction proceeds relatively more thoroughly from, the system to 2 - a certain extent 2 - by reducing the reaction proceeds, to relatively more thoroughly; NaOH, NaCl, and. (by machine translation)

Method for preparing high-purity 4-hydroxyethylpiperazine ethanesulfonic acid

The invention belongs to the technical field of preparation of organic matters, and relates to a method for preparing high-purity 4-hydroxyethylpiperazine ethanesulfonic acid. The method sequentially comprises the following specific steps: preparation of 4-hydroxyethylpiperazine ethanesulfonate, acidizing, extraction for decolorizing and removing impurities, reverse extraction, nanofiltration and washing, and drying, so that the high-purity 4-hydroxyethylpiperazine ethanesulfonic acid is finally obtained. The 4-hydroxyethylpiperazine ethanesulfonic acid prepared with the method provided by the invention is high in purity; the operation process is simple and convenient; the production process is environmentally friendly; the purification cost is low; the yield is high; the method is suitable for industrial batch production.

High purity 4 - hydroxyethyl piperazine b sulfonic acid

The invention belongs to the technical field of organic matter preparation, and particularly relates to a method for preparing high-purity 4-hydroxyethyl piperazine ethane sulfonic acid. The method comprises the following steps: carrying out addition reaction on vinylsulfonic acid or vinyl sulfonate and N-hydroxyethyl piperazine to prepare 4-hydroxyethylpiperazine ethane sulfonate; converting the 4-hydroxyethylpiperazine ethane sulfonate into 4-hydroxyethylpiperazine ethane sulfonic acid and corresponding salts of an acidifier by adopting the acidifier, thus obtaining acidifying mother liquor; then crystallizing to remove the corresponding salts of the acidifier to obtain processed acidifying mother liquor; adding soluble barium salt or calcium salt to the processed acidifying mother liquor to remove residual sulfate radicals, and carrying out evaporative concentration to obtain a primary purified product of the 4-hydroxyethylpiperazine ethane sulfonic acid; finally, washing the primary purified product by adopting small molecular weight alcohol and drying to obtain the high-purity 4-hydroxyethylpiperazine ethane sulfonic acid. The 4-hydroxyethylpiperazine ethane sulfonic acid prepared by the method disclosed by the invention is high in purity, simple and convenient in operation process, environment-friendly in production process, low in purification cost, high in yield and suitable for industrial batch production.

COAGULATION FACTOR VII POLYPEPTIDES

The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.

Peptides for Treatment of Obesity

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

Stabilizing labeled antibody using amino acids

The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution.

Isolation of nucleic acids

A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.

Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions

Zwitterionic compounds selected from: taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido)iminodiacetic acid (ADA), piperazine-N,N'bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS), 2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.

Use of zwitterionic compounds and their N-halo derivatives

Zwitterionic compounds selected from:, taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido) iminodiacetic acid (ADA), piperazine-N,N?bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N?-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N?3-propanesulphonic acid ((H)EPPS), 2-(cyclohexylamino) ethanesulphonic acid (CHES) or 3-(cyclohexylamino) propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter aliato enhanced leukotriene inactivation.